Compare MP & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MP | ABVX |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | France |
| Employees | N/A | 69 |
| Industry | Metal Mining | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 11.9B |
| IPO Year | 2020 | N/A |
| Metric | MP | ABVX |
|---|---|---|
| Price | $45.30 | $136.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 13 |
| Target Price | $75.25 | ★ $131.31 |
| AVG Volume (30 Days) | ★ 4.3M | 2.2M |
| Earning Date | 05-07-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $331,952,000.00 | N/A |
| Revenue This Year | $100.51 | $52.14 |
| Revenue Next Year | $60.41 | $4,132.27 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 147.15 | N/A |
| 52 Week Low | $44.43 | $9.96 |
| 52 Week High | $100.25 | $148.83 |
| Indicator | MP | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 31.17 | 60.02 |
| Support Level | $44.43 | $106.03 |
| Resistance Level | $64.62 | $148.41 |
| Average True Range (ATR) | 2.82 | 5.36 |
| MACD | -0.62 | 0.81 |
| Stochastic Oscillator | 9.97 | 78.92 |
MP Materials Corp is the producer of rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility, the only rare earth mining and processing site of scale in North America. The company is also developing a rare earth metal, alloy, and magnet manufacturing facility in Fort Worth, Texas. The company's operations are organized into two reportable segments: Materials and Magnetics.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.